Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Iveric Bio

Astellas’ Izervay Joins Geographic Atrophy Market, Intensifying Competition

The C5 inhibitor, recently acquired by Astellas, will be commercially available in two to four weeks and will compete against Apellis Pharma’s Syfovre.

Ophthalmic Launches

Japan Q1 Roundup: High Hopes For Leqembi And Veozah, Forex Give And Take

Daiichi Sankyo, Chugai and Shionogi all marked double-digit revenue growth in the fiscal first quarter, while Astellas and Takeda saw some slow down. New products including Veozah and Leqembi buoyed performances, while the the expected upcoming US approval of a subcutaneous formulation may help restore Entyvio’s growth trajectory.

Japan Sales & Earnings

Apellis’ Syfovre Sales Overshadowed By Safety Concerns

Second quarter sales of the new geographic atrophy drug exceeded expectations, but the company confirmed seven events of retinal vasculitis in patients treated with Syfovre in the real world.

Safety Ophthalmic

Hopes Inch Higher For Annexon’s AMD Candidate After New Phase II Analyses

The US biotech’s ANX007 has some analysts cautiously optimistic as post hoc Phase II analyses backed its ability to improve visual acuity in geographic atrophy secondary to age-related macular edema despite a prior primary endpoint miss.

Clinical Trials Ophthalmic
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Inception 4, Inc.
    • Ophthotech Corporation (OPHT)